.png)
SummaryThis analysis is based on the current price data from the pharmazie.com PharMonitor, comparing the 1 July 2026 effective date with the previous one, 15 June 2026. 1 July is rarely an ordinary date in the drug market, and in 2026 it is not, for three reasons. On this day three drivers act on prices at once: a structural one (the new pharmacy fee), a plannable one (the annual inflation adjustment) and a market-driven one (the continuing downward pressure on generics, biosimilars and imports). Each is known on its own; only together do they give the full picture. We evaluated the data before the effective date and its publication. It is written for professionals, not patients.
| Metric | 1 July 2026 | What lies behind it |
|---|---|---|
| Observed PZNs with a price update | 69,018 | All products updated on the date |
| of which through the new pharmacy fee alone | 56,628 | Selling price +€0.77 / €0.78, no manufacturer-price change |
| Real manufacturer-price changes (domestic) | 5,229 | Actual manufacturer pricing decisions |
| → increases | 2,669 (51%) | avg. +4.3% · median +2.2% |
| → cuts | 2,560 (49%) | avg. -10.1% · median -5.8% |
| Parallel / re-imports (viewed separately) | 3,277 | mostly cheaper, avg. -1.4% |
Two metrics per direction: the average (avg.) means all moves including extremes and shows the total force; the median is the middle value unaffected by outliers. For cuts, the average is -10.1% because some products fall very sharply, while half the cuts stay milder than -5.8%.
All changes refer to the direct comparison with the previous date, 15 June 2026. In number, increases and cuts among domestic prices are almost level (51 to 49). What is decisive is the force, not the count: increases are mostly moderate (most often +2.2%), while cuts are more than twice as strong, with nearly four in ten in double digits. Adding the parallel imports, the overall balance clearly tips downward.
The most striking effect concerns not manufacturers but pharmacies. 56,628 prescription medicines rise in pharmacy selling price by a constant +€0.77 to €0.78, while purchase and manufacturer prices stay unchanged. This separation matters: the selling price contains, besides the purchase price, the pharmacy surcharge and VAT. If only it changes, the cause is not the manufacturer but the remuneration. On 1 July the pharmacy per-pack fee rises from €8.35 to €9.00 net, the first increase since 2013.1 The arithmetic is exact: net +€0.65 with 19% VAT gives the +€0.77 / €0.78 gross that appears across the data. A second step to €9.50 follows on 1 January 2027.1 For pharmacies this is a long-awaited fee boost; for the GKV a cost factor, with the first step alone summing, across around 640 million Rx packs in the second half of 2026, to roughly €250 million in additional GKV spending (gross).2 Read wrongly, this effect looks like more than 56,000 price increases, where in truth no manufacturer price rose at all.
Among the real manufacturer increases a pattern stands out: 1,787 medicines become exactly +2.2% dearer, and about three quarters of all increases fall in the narrow corridor between +2.0% and +2.5%. Behind this is the price-moratorium inflation adjustment (section 130a(3a) SGB V).3 Since 2009 the manufacturer selling prices of many medicines are frozen by law; as compensation for inflation, manufacturers may raise the frozen level once a year, on 1 July, by the previous year's inflation, without paying the full mandatory rebate. The adjustment factor is not negotiable but officially set: the annual-average consumer price index, which for 2025 was exactly +2.2%.4 This value now appears thousands of times in the data. The peak is clearly an Rx phenomenon: 88% of the exact +2.2% increases are prescription-only. The mechanism applies only to GKV-reimbursable medicines without a reference price; parallel and re-imports follow special rules (section 130a(3a) sentence 6 SGB V). How large this small step can become is shown by the most expensive products: enzyme-replacement therapies such as Cerezyme, VPRIV or Fabrazyme each add over €1,000 per pack in the large sizes through the same 2.2%, the same percentage on a very different level.
While the fee and the inflation adjustment push up, a third driver pulls down. Unlike the first two it is not regulatory but arises from competition itself: generic and biosimilar rivalry, group-wide reference-price adjustments and price erosion in parallel imports. Excluding the inflation adjustment, cuts clearly predominate across all domestic moves, around three quarters, and are stronger than the increases (avg. -10.1% / median -5.8% against avg. +8.6% / median +3.1%). The segment view shows where the pressure acts most strongly, with the inflation adjustment removed for Rx and biosimilars.
| Segment | Avg. price change | Share increasing | Share cutting | Increase quota | Cut quota | Tendency |
|---|---|---|---|---|---|---|
| Rx (prescription) | -6.6% | 1.3% | 6.4% | 17% | 83% | Sustained price pressure |
| OTC (non-prescription) | +4.4% | 27.8% | 0.1% | 99% | 1% | Clear upward trend |
| Import / re-import | -1.4% | 1.4% | 11.8% | 11% | 89% | Price correction |
| Biosimilars / biotech | -3.0% | 1.2% | 14.5% | 7% | 93% | Competitive pressure |
The share columns give the proportion of all observed products in the segment; the quota columns give the direction among the products that actually moved. In OTC only part of the range moves, but when it does it is almost always upward, broadly across pharmacy-typical groups. The counterpart is biosimilars and imports, where the market-driven pressure is clearest: with the inflation adjustment removed, domestic biotech products fall by an average of -7.6%, and around 86% of moves are cuts. A visible driver is the mandatory biosimilar substitution under section 40c of the G-BA drug directive (in force since 1 April 2026, based on section 129 SGB V).8 For parallel imports, sourcing and exchange rates add to the dynamic.
A single price fall says little on its own. The decisive question is always: does only one supplier cut, or the whole active-ingredient group? The ATC classification held in the data provides the answer. For the Parkinson's agent rasagiline (ATC N04BD02), 46 of 84 packs change price, originator and generics together, towards a new, lower level. That is not one manufacturer acting alone but a group-wide effect, typically a reference-price adjustment. Looking only at the single PZN, one might take it for an aggressive individual decision; the group view shows the actual mechanism.
Price moves do not arise in a vacuum, and one obvious context is supply shortages. As of 26 June 2026, the retrieval date of the shortage list, the BfArM list records 958 active notifications for 945 products, concentrated in the nervous system (378), cardiovascular (154) and oncology/immunomodulation (84), of which 247 are hospital-relevant.5 Here we leave the pure data level and interpret with due caution: around a quarter of the increases above 10% concern an active ingredient for which an active shortage is simultaneously reported. In one especially clear case both coincide in the same product: the calcium antagonist nitrendipine (supplier Aristo) rises drastically, the 10 mg pack jumping from €0.80 to €2.55 manufacturer selling price (+219%, the largest single move of the whole date), and exactly these packs are currently reported as not deliverable (BfArM reasons: increased demand for the 10 mg, batch-testing problems for the 20 mg strength). Scarcity, rising demand and a price increase meet here in the same active ingredient. A causal link cannot be proven from this, but it is exactly the pattern that only becomes visible when price and shortage data are read together. More striking still is the combination of shortage and rebate contract: some 30 of the clear increases (>10%) concern an active ingredient with an active shortage and also carry a rebate-contract flag. One expressly hypothetical explanation would be that manufacturers secure stock and price under threatened scarcity to avoid rebate-contract penalties.
Vaccines (ATC J07) appear with 959 products in the price data, 92 of them with a price change, almost balanced (38 up, 54 down). Because the BfArM list does not cover vaccines, we additionally check shortages at the Paul-Ehrlich-Institut: as of 26 June 2026 there are no complete vaccine shortages, only three unavailable single packs (Priorix-Tetra, Varilrix, Heplisav B), each with an available alternative and no price change.6 There is thus no connection between vaccine shortages and prices this month.
On the effective date 238 medicines newly enter the data and 54 disappear. The introductions concentrate in oncology/immunomodulation (53), the nervous system (35) and cardiovascular (26); the specialist and patent market remains the most dynamic part of the picture.
Wholesale and trade: every day of lead time counts. On cuts, stock loses value. This date gives clear examples: the gene therapy Roctavian loses around €2,582 per pack, a nintedanib generic over €1,500, a ustekinumab biosimilar (Yesintek) around €1,252. Knowing such moves up to five days earlier lets you sell down stock at the old value and actively protect inventory value.
Pharmaceutical industry and manufacturers: the July window is unique. The inflation adjustment (+2.2% for 2026) can be taken only once a year; unused it forfeits permissible headroom, misapplied it risks discounts under section 130a SGB V. Equally important is the view of one's own ATC group: who is cutting, who is holding, where is the group converging on a new reference-price level?
Pharmacies: margin and retax safety from day one. With the €9.00 fee, the selling price of practically every Rx pack changes. Correct prices and retax safety require the new values to be in the system exactly on the date.
Payers and market access: spot convergence early. Reference-price convergence, biosimilar erosion and group-wide moves are visible only to those who read single PZN and ATC group together, the basis for robust pricing and tender decisions.
1 July 2026 shows the German drug market in rarely concentrated form. A structural adjustment, the higher pharmacy fee, moves almost every pharmacy pack without changing a single manufacturer price. A plannable step, the +2.2% inflation adjustment, lifts thousands of manufacturer prices by exactly the same value. And beneath them the market-driven downward pressure on biosimilars and imports continues unchanged. To read individual price moves correctly, you must keep all three apart, which only current, complete data makes possible. This analysis is based on the day-current price data of the pharmazie.com PharMonitor, available up to five days before the official publication on the effective date, with price alerts, segment and ATC analyses and a historical price archive, exclusively for healthcare professionals.
Evaluated were the delta data of the pharmazie.com PharMonitor for the 1 July 2026 effective date: 69,018 records whose entry was updated on the date. Each comparison is against the previous date (15 June 2026); the file holds the respective previous value for each changed price. The real manufacturer price is the ApU column; after excluding non-medicines, price-to-zero cases (23), re-introductions and parallel/re-imports (shown separately), 8,506 real manufacturer-price changes for medicines remain. The ATC group is taken directly from the stored active-ingredient identifier, data-based, not estimated. All values are list prices; actual reimbursement prices can differ considerably through rebate contracts. Composition of the 69,018 records: 56,628 pure fee effects, 8,506 real manufacturer-price changes (5,229 domestic + 3,277 parallel/re-imports), and 3,884 not direction-relevant (2,415 master-data updates without price change, 1,455 non-medicines, 14 special cases). A BfArM shortage notification counts as active if its end date is on or after the retrieval date (26 June 2026) and it is not a deletion notice (958 active notifications, 945 products).
Data basis: pharmazie.com PharMonitor (effective date 1 July 2026).
1 Third Regulation amending the Arzneimittelpreisverordnung of 9 June 2026 (BGBl. 2026 I No. 173, promulgated 12 June 2026): section 3(1) AMPreisV, fee €8.35 → €9.00 from 1 July 2026, → €9.50 from 1 January 2027. recht.bund.de
2 Explanatory memorandum to the third AMPreisV amendment (approx. €250 million additional GKV spending at around 640 million Rx packs).
3 Section 130a(3a) SGB V (price moratorium and inflation adjustment). gesetze-im-internet.de
4 Statistisches Bundesamt (Destatis): consumer price index, annual average 2025 = +2.2% against 2024. destatis.de
5 BfArM shortage list for human medicines (excluding vaccines), as of 26 June 2026. pharmnet-bund.de
6 Paul-Ehrlich-Institut (PEI): shortages of human vaccines, as of 26 June 2026. pei.de
8 Gemeinsamer Bundesausschuss (G-BA): drug directive section 40c (biologicals substitution in pharmacies), decision of 4 December 2025, in force since 1 April 2026; basis section 129 SGB V. g-ba.de
Interpretive statements on shortages and rebate contracts are marked as hypotheses; no causal link is asserted.
